Loading...
Loading...
LifeTech Capital raised its Echo Therapeutics
ECTE price target to $6 from $4.50 and maintained Echo Therapeutics Strong Speculative Buy rating in a research report published today.
In the report, LifeTech Capital states, "Echo Therapeutics Symphony™ transdermal continuous glucose monitor (tCGM) system is a unique needle-free, wireless system which we believe is set to begin a pivotal clinical trial in ICU/Critical Care patients during 2011 (following a final pilot trial). We believe this puts Echo Therapeutics ahead of the curve with respect to tougher FDA standards for hospital use."
Shares of Echo Therapeutics closed Friday at $4.25, down 9.96% from Thursday's market close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in